Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Fast Track Articles
  5. Fast Track Article
image of Plant-based Therapeutics for Aspergillus Co-infections in COVID-19 Patients Illuminating Phytochemical Mechanisms

Abstract

The emergence of COVID-19 has highlightedthe issue of secondary fungal infections, such as COVID-19-Associated invasive Pulmonary Aspergillosis (CAPA), in critically ill patients. Continuous use of therapies employing steroids and immune-modulating agents has increased the risk of co-infections resulting from fungi, further weakening the respiratory systems of patients and leading to complex situations such as multi-organ failure and elevated mortality. The increasing occurrence of antifungal resistance in strains has made the management of these infections challenging, highlighting the need for novel and effective antifungal agents. Plants and their bioactive compounds offer promising alternatives to conventional antifungal medications. Phytochemicals such as 1,8-cineole from , thymol from commercial extracts, and cinnamaldehyde from have demonstrated significant antifungal activities by targeting fungal cell walls, membranes, and gene expression. Additionally, compounds like eugenol from and citral from exhibit potent antimicrobial effects by disrupting cellular integrity. However, challenges such as variability in phytochemical content, limited clinical data, and potential drug interactions must be addressed. This review explores the potential of plant-based medicines for treating aspergillosis, emphasizing the need for further research to validate their effectiveness, safety, and optimal dosages through clinical studies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975333157241227074402
2025-01-06
2025-03-01

  • From This Site

    /content/journals/covid/10.2174/0126667975333157241227074402
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Hu B. Guo H. Zhou P. Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021 19 3 141 154 10.1038/s41579‑020‑00459‑7 33024307
    [Google Scholar]
  2. Mohamed A. Rogers T.R. Talento A.F. COVID-19 associated invasive pulmonary aspergillosis: Diagnostic and therapeutic challenges. J. Fungi 2020 6 3 115 10.3390/jof6030115 32707965
    [Google Scholar]
  3. Koehler P. Bassetti M. Chakrabarti A. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. 2021 21 6 e149 e162 10.1016/S1473‑3099(20)30847‑1 33333012
    [Google Scholar]
  4. Kitayama T Tone K Makimura K Takagi M Kuwano K. COVID-19-associated pulmonary aspergillosis complicated by severe coronavirus disease: Is Detection of Aspergillus in Airway Specimens Before Disease Onset an Indicator of Antifungal Prophylaxis? Nat. Rev. Microbiol. 2023 15 3 e36212 10.7759/cureus.36212 37069870
    [Google Scholar]
  5. Fisher M.C. Alastruey-Izquierdo A. Berman J. Bicanic T. Bignell E.M. Bowyer P. Bromley M. Brüggemann R. Garber G. Cornely O.A. Gurr S.J. Harrison T.S. Kuijper E. Rhodes J. Sheppard D.C. Warris A. White P.L. Xu J. Zwaan B. Verweij P.E. Tackling the emerging threat of antifungal resistance to human health. Nat. Rev. Microbiol. 2022 20 9 557 571 10.1038/s41579‑022‑00720‑1 35352028
    [Google Scholar]
  6. Talbot J.J. Frisvad J.C. Meis J.F. Hagen F. Verweij P.E. Hibbs D.E. Lai F. Groundwater P.W. Samson R.A. Kidd S.E. Barrs V.R. Houbraken J. Cyp51A mutations, extrolite profiles, and antifungal susceptibility in clinical and environmental isolates of the aspergillus viridinutans species complex. Anti. Agen. Chem. 2019 63 11 e00632-19 10.1128/AAC.00632‑19 31451501
    [Google Scholar]
  7. Walker L.A. Gow N.A.R. Munro C.A. Fungal echinocandin resistance. Fungal Genet. Biol. 2010 47 2 117 126 10.1016/j.fgb.2009.09.003 19770064
    [Google Scholar]
  8. Healey K.R. Perlin D.S. Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata. J. Fungi 2018 4 3 105 10.3390/jof4030105 30200517
    [Google Scholar]
  9. Gizaw A Marami LM Teshome I Phytochemical Screening and in vitro antifungal activity of selected medicinal plants against candida albicans and aspergillus niger in west shewa zone, ethiopia. Adv. Phar. Pha. Sci. 2022 2022 3299146 10.1155/2022/3299146 35800399
    [Google Scholar]
  10. Behiry S.I. Hamad N.A. Alotibi F.O. Al-Askar A.A. Arishi A.A. Kenawy A.M. Elsamra I.A. Youssef N.H. Elsharkawy M.M. Abdelkhalek A. Heflish A.A. Antifungal and antiaflatoxigenic activities of different plant extracts against aspergillus flavus. Sustainability 2022 14 19 12908 10.3390/su141912908
    [Google Scholar]
  11. Tripathi S. Morya V. Prakash V. Profiling of antifungal activities from the leaf extract of selected apiaceae family plants against aspergillus fumigates. Am. J. Plant Sci. 2023 14 1 1 14 10.4236/ajps.2023.141001
    [Google Scholar]
  12. Chtioui W. Heleno S. Migheli Q. Rodrigues P. Plant extracts as biocontrol agents against Aspergillus carbonarius growth and ochratoxin A production in grapes. Int. J. Foo. Micro. 2023 407 110425 10.1016/j.ijfoodmicro.2023.110425 37804776
    [Google Scholar]
  13. Maj W. Pertile G. Różalska S. Skic K. Frąc M. Comprehensive antifungal investigation of natural plant extracts against neosartorya spp. (aspergillus spp.) of agriculturally significant microbiological contaminants and shaping their metabolic profile. Sci. Rep. 2024 14 1 8399 10.1038/s41598‑024‑58791‑4 38600229
    [Google Scholar]
  14. Singapurwa N.M.A.S. Candra I.P. Antimicrobial activity of garlic and Kaempferia galanga on Aspergillus sp. growth isolated from sardine fish Pedetan. IOP Confer. Seri.: Earth Environ. Sci. 2021 824 1 012037 10.1088/1755‑1315/824/1/012037
    [Google Scholar]
  15. Wang M. Liu H. Dang Y. Li D. Qiao Z. Wang G. Liu G. Xu J. Li E. Antifungal mechanism of cinnamon essential oil against chinese yam-derived aspergillus niger. J. Food Process. Preserv. 2023 2023 1 9 10.1155/2023/5777460 29967599
    [Google Scholar]
  16. Muñoz Castellanos L. Amaya Olivas N. Ayala-Soto J. In vitro and in vivo antifungal activity of clove (eugenia caryophyllata) and pepper (piper nigrum l.) essential oils and functional extracts against Fusarium oxysporum and Aspergillus niger in Tomato (Solanum lycopersicum L.). Int. J. Microbiol. 2020 1702037 10.1155/2020/1702037 32399036
    [Google Scholar]
  17. Zhang D. Yang Y. Yao B. Hu T. Ma Z. Shi W. Ye Y. Curcumin inhibits Aspergillus flavus infection and aflatoxin production possibly by inducing ROS burst. Food Res. Int. 2023 167 112646 10.1016/j.foodres.2023.112646 37087237
    [Google Scholar]
  18. Sharma A.D. Kaur I. Chauhan A. Anti-aspergillosis and anti-mucormycosis potential of eucalyptus essential oil based O/W nanoemulsions containing azole based drugs from Eucalyptus globulus. J. Umm Al-Qura Univer. Appl. Sci. 2024 10 2 313 329 10.1007/s43994‑023‑00108‑8
    [Google Scholar]
  19. Devecioglu D. Turker M. Karbancioglu-Guler F. Antifungal activities of different essential oils and their electrospun nanofibers against Aspergillus and Penicillium species isolated from bread. ACS Omega 2022 7 42 37943 37953 10.1021/acsomega.2c05105 36312428
    [Google Scholar]
  20. Abd El-Hack M.E. Kamal M. Altaie H.A.A. Youssef I.M. Algarni E.H. Almohmadi N.H. Abukhalil M.H. Khafaga A.F. Alqhtani A.H. Swelum A.A. Peppermint essential oil and its nano-emulsion: Potential against aflatoxigenic fungus Aspergillus flavus in food and feed. Toxicon 2023 234 107309 10.1016/j.toxicon.2023.107309 37802220
    [Google Scholar]
  21. Morcia C. Malnati M. Terzi V. In vitro antifungal activity of terpinen-4-ol, eugenol, carvone, 1,8-cineole (eucalyptol) and thymol against mycotoxigenic plant pathogens. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 2012 29 3 415 422 22257275
    [Google Scholar]
  22. Leontiev R. Hohaus N. Jacob C. Gruhlke M.C.H. Slusarenko A.J. A comparison of the antibacterial and antifungal activities of thiosulfinate analogues of allicin. Sci. Rep. 2018 8 1 6763 10.1038/s41598‑018‑25154‑9 29712980
    [Google Scholar]
  23. Patterson T.F. Advances and challenges in management of invasive mycoses. Lancet 2005 366 9490 1013 1025 10.1016/S0140‑6736(05)67381‑3 16168784
    [Google Scholar]
  24. Latgé J.P. Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin. Microbiol. Rev. 2019 33 1 e00140-18 10.1128/CMR.00140‑18 31722890
    [Google Scholar]
  25. Adeoye A.O. Lateef A. Biotechnological valorization of cashew apple juice for the production of citric acid by a local strain of Aspergillus niger LCFS 5. J. Genet. Eng. Biotechnol. 2021 19 1 137 10.1186/s43141‑021‑00232‑0 34533689
    [Google Scholar]
  26. Barnes A.J. Denning D.W. Aspergilli — significance as pathogens. Rev. Med. Microbiol. 1993 4 3 176 180 10.1097/00013542‑199307000‑00009
    [Google Scholar]
  27. Krishnan S. Manavathu E.K. Chandrasekar P.H. Aspergillus flavus : An emerging non‐ fumigatus Aspergillus species of significance. Mycoses 2009 52 3 206 222 10.1111/j.1439‑0507.2008.01642.x 19207851
    [Google Scholar]
  28. Hyde K.D. Abd-Elsalam K. Cai L. Morphology: Still essential in a molecular world. Mycotaxon 2011 114 1 439 451 10.5248/114.439
    [Google Scholar]
  29. Krijgsheld P. Bleichrodt R. van Veluw G.J. Wang F. Müller W.H. Dijksterhuis J. Wösten H.A.B. Development in aspergillus. Stud. Mycol. 2013 74 1 1 29 10.3114/sim0006 23450714
    [Google Scholar]
  30. Frisvad J.C. Larsen T.O. Extrolites of aspergillus fumigatus and other pathogenic species in aspergillus section fumigati. Front. Microbiol. 2016 6 1485 10.3389/fmicb.2015.01485 26779142
    [Google Scholar]
  31. Garbino J. Lew D. Aspergillosis. Creation date. Lew P.D. University of Geneva Hospitals Geneva, Switzerland 2004 1496 1499
    [Google Scholar]
  32. Hedayati M.T. Pasqualotto A.C. Warn P.A. Bowyer P. Denning D.W. Aspergillus flavus: Human pathogen, allergen and mycotoxin producer. Microbiology 2007 153 6 1677 1692 10.1099/mic.0.2007/007641‑0 17526826
    [Google Scholar]
  33. Robertson M.J. Larson R.A. Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am. J. Med. 1988 84 2 233 239 10.1016/0002‑9343(88)90419‑6 3407652
    [Google Scholar]
  34. Palmieri F. Koutsokera A. Bernasconi E. Junier P. von Garnier C. Ubags N. Recent advances in fungal infections: from lung ecology to therapeutic strategies with a focus on Aspergillus spp. Front. Med. 2022 9 832510 10.3389/fmed.2022.832510 35386908
    [Google Scholar]
  35. Gibson A.M. Baranyi J. Pitt J.I. Eyles M.J. Roberts T.A. Predicting fungal growth: The effect of water activity on Aspergillus flavus and related species. Int. J. Food Microbiol. 1994 23 3-4 419 431 10.1016/0168‑1605(94)90167‑8 7873341
    [Google Scholar]
  36. Ranaweera A. American thoracic society. Int. J. Pharm. Med. 2005 19 3 173 177 10.2165/00124363‑200519030‑00005
    [Google Scholar]
  37. Stevens D.A. Kan V.L. Judson M.A. Morrison V.A. Dummer S. Denning D.W. Bennett J.E. Walsh T.J. Patterson T.F. Pankey G.A. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 2000 30 4 696 709 10.1086/313756 10770732
    [Google Scholar]
  38. Wong R.S.Y. Inflammation in COVID-19: from pathogenesis to treatment. Int. J. Clin. Exp. Pathol. 2021 14 7 831 844 34367415
    [Google Scholar]
  39. Ben-Ami R. Lewis R.E. Kontoyiannis D.P. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br. J. Haematol. 2010 150 4 406 417 10.1111/j.1365‑2141.2010.08283.x 20618330
    [Google Scholar]
  40. Rudramurthy S.M. Paul R.A. Chakrabarti A. Mouton J.W. Meis J.F. Invasive aspergillosis by Aspergillus flavus: Epidemiology, diagnosis, antifungal resistance, and management. J. Fungi 2019 5 3 55 10.3390/jof5030055 31266196
    [Google Scholar]
  41. Yu J. Cleveland T.E. Nierman W.C. Bennett J.W. Aspergillus flavus genomics: gateway to human and animal health, food safety, and crop resistance to diseases. Rev. Iberoam. Micol. 2005 22 4 194 202 10.1016/S1130‑1406(05)70043‑7 16499411
    [Google Scholar]
  42. Rajendran C. Basu T.K. Baby A. Kumari S. Verghese T. Incidence and significance of opportunistic fungi in leukemia patients in India. Mycopathologia 1992 119 2 83 87 10.1007/BF00443938 1435951
    [Google Scholar]
  43. Chakrabarti A. Gupta V. Biswas G. Kumar B. Sakhuja V.K. Primary cutaneous asperigillosis: our experience in 10 years. J. Infect. 1998 37 1 24 27 10.1016/S0163‑4453(98)90303‑6 9733373
    [Google Scholar]
  44. Chakrabarti A. Sharma S.C. Chander J. Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol. Head Neck Surg. 1992 107 6P1 745 750 10.1177/019459988910700606.1 1470451
    [Google Scholar]
  45. Garg P. Mahesh S. Bansal A.K. Gopinathan U. Rao G.N. Fungal infection of sutureless self-sealing incision for cataract surgery. Ophthalmology 2003 110 11 2173 2177 10.1016/S0161‑6420(03)00861‑3 14597526
    [Google Scholar]
  46. Kaushik S. Ram J. Brar G.S. Jain A.K. Chakraborti A. Gupta A. Intracameral amphotericin B: initial experience in severe keratomycosis. Cornea 2001 20 7 715 719 10.1097/00003226‑200110000‑00009 11588423
    [Google Scholar]
  47. Sridhar M.S. Garg P. Bansal A.K. Gopinathan U. Aspergillus flavus keratitis after laser in situ keratomileusis. Am. J. Ophthalmol. 2000 129 6 802 804 10.1016/S0002‑9394(00)00406‑2 10926994
    [Google Scholar]
  48. Sridhar M.S. Gopinathan U. Rao G.N. Fungal keratitis associated with vernal keratoconjunctivitis. Cornea 2003 22 1 80 81 10.1097/00003226‑200301000‑00020 12502957
    [Google Scholar]
  49. Mukherji S.K. Figueroa R.E. Ginsberg L.E. Zeifer B.A. Marple B.F. Alley J.G. Cooper L.L. Nemzek W.R. Yousem D.M. Jones K.R. Kupferberg S.B. Castillo M. Allergic fungal sinusitis: CT findings. Radiology 1998 207 2 417 422 10.1148/radiology.207.2.9577490 9577490
    [Google Scholar]
  50. Chhabra A. Handa K.K. Chakrabarti A. Mann S.B.S. Panda N. Allergic fungal sinusitis: clinicopathological characteristics. Mycoses 1996 39 11-12 437 441 10.1111/j.1439‑0507.1996.tb00093.x 9145000
    [Google Scholar]
  51. Taj-Aldeen SJ Hilal AA Schell WA Allergic fungal rhinosinusitis: A report of 8 cases. Am J Otolaryngol - Head Neck Med Surg 2004 25 3 213 218 10.1016/j.amjoto.2003.12.003 15124174
    [Google Scholar]
  52. Saravanan K. Panda N.K. Chakrabarti A. Das A. Bapuraj R.J. Allergic fungal rhinosinusitis: an attempt to resolve the diagnostic dilemma. Arch. Otolaryngol. Head Neck Surg. 2006 132 2 173 178 10.1001/archotol.132.2.173 16490875
    [Google Scholar]
  53. Pasqualotto A.C. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med. Mycol. 2009 47 s1 Suppl. 1 S261 S270 10.1080/13693780802247702 18654921
    [Google Scholar]
  54. Haldane V. De Foo C. Abdalla S.M. Jung A.S. Tan M. Wu S. Chua A. Verma M. Shrestha P. Singh S. Perez T. Tan S.M. Bartos M. Mabuchi S. Bonk M. McNab C. Werner G.K. Panjabi R. Nordström A. Legido-Quigley H. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat. Med. 2021 27 6 964 980 10.1038/s41591‑021‑01381‑y 34002090
    [Google Scholar]
  55. Davis H.E. McCorkell L. Vogel J.M. Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023 21 3 133 146 10.1038/s41579‑022‑00846‑2 36639608
    [Google Scholar]
  56. Negm E.M. Mohamed M.S. Rabie R.A. Fouad W.S. Beniamen A. Mosallem A. Tawfik A.E. Salama H.M. Fungal infection profile in critically ill COVID-19 patients: a prospective study at a large teaching hospital in a middle-income country. BMC Infect. Dis. 2023 23 1 246 10.1186/s12879‑023‑08226‑8 37072718
    [Google Scholar]
  57. Gibson P.G. Qin L. Puah S.H. COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐ COVID‐19 ARDS. Med. J. Aust. 2020 213 2 54 56.e1 10.5694/mja2.50674 32572965
    [Google Scholar]
  58. Arastehfar A. Carvalho A. van de Veerdonk F.L. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J. Fungi 2020 6 1 17 10.3390/jof6020091
    [Google Scholar]
  59. Rutsaert L. Steinfort N. Van Hunsel T. Bomans P. Naesens R. Mertes H. Dits H. Van Regenmortel N. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care 2020 10 1 71 10.1186/s13613‑020‑00686‑4 32488446
    [Google Scholar]
  60. Louis TJ Qasem A Abdelli LS Naser SA Extra-pulmonary complications in SARS-CoV-2 infection: A comprehensive multi organ-system review. Microorg 2022 10 1 153 10.3390/microorganisms10010153 35056603
    [Google Scholar]
  61. Bhatt K. Agolli A. Patel M.H. Garimella R. Devi M. Garcia E. Amin H. Domingue C. Guerra Del Castillo R. Sanchez-Gonzalez M. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries 2021 9 1 e126 10.15190/d.2021.5 34036149
    [Google Scholar]
  62. Dimopoulos G. Almyroudi M.P. Myrianthefs P. Rello J. COVID-19-associated pulmonary aspergillosis (CAPA). J. Inten. Medi. 2021 1 2 71 80 10.1016/j.jointm.2021.07.001 36785564
    [Google Scholar]
  63. Kasuga Y. Zhu B. Jang K.J. Yoo J.S. Innate immune sensing of coronavirus and viral evasion strategies. Exp. Mol. Med. 2021 53 5 723 736 10.1038/s12276‑021‑00602‑1 33953325
    [Google Scholar]
  64. Smith N. Possémé C. Bondet V. Sugrue J. Townsend L. Charbit B. Rouilly V. Saint-André V. Dott T. Pozo A.R. Yatim N. Schwartz O. Cervantes-Gonzalez M. Ghosn J. Bastard P. Casanova J.L. Szwebel T.A. Terrier B. Conlon N. O’Farrelly C. Cheallaigh C.N. Bourke N.M. Duffy D. Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. Nat. Commun. 2022 13 1 7254 10.1038/s41467‑022‑34895‑1 36434007
    [Google Scholar]
  65. Kervevan J. Chakrabarti L.A. Role of cd4+ T cells in the control of viral infections: Recent advances and open questions. Int. J. Mol. Sci. 2021 22 2 523 10.3390/ijms22020523 33430234
    [Google Scholar]
  66. Jordan S.C. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clin. Exp. Immunol. 2021 204 3 310 320 10.1111/cei.13582 33534923
    [Google Scholar]
  67. Ragab D. Salah Eldin H. Taeimah M. Khattab R. Salem R. The COVID-19 cytokine storm; What we know so far. Front. Immunol. 2020 11 1446 10.3389/fimmu.2020.01446 32612617
    [Google Scholar]
  68. Zhao N. Di B. Xu L. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021 61 2 15 10.1016/j.cytogfr.2021.06.002 34183243
    [Google Scholar]
  69. Hussain A. Yang H. Zhang M. Liu Q. Alotaibi G. Irfan M. He H. Chang J. Liang X.J. Weng Y. Huang Y. mRNA vaccines for COVID-19 and diverse diseases. J. Control. Release 2022 345 314 333 10.1016/j.jconrel.2022.03.032 35331783
    [Google Scholar]
  70. Sadoff J. Gray G. Vandebosch A. Cárdenas V. Shukarev G. Grinsztejn B. Goepfert P.A. Truyers C. Fennema H. Spiessens B. Offergeld K. Scheper G. Taylor K.L. Robb M.L. Treanor J. Barouch D.H. Stoddard J. Ryser M.F. Marovich M.A. Neuzil K.M. Corey L. Cauwenberghs N. Tanner T. Hardt K. Ruiz-Guiñazú J. Le Gars M. Schuitemaker H. Van Hoof J. Struyf F. Douoguih M. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N. Engl. J. Med. 2021 384 23 2187 2201 10.1056/NEJMoa2101544 33882225
    [Google Scholar]
  71. Heidary M. Kaviar V.H. Shirani M. Ghanavati R. Motahar M. Sholeh M. Ghahramanpour H. Khoshnood S. A comprehensive review of the protein subunit vaccines against COVID-19. Front. Microbiol. 2022 13 927306 10.3389/fmicb.2022.927306 35910658
    [Google Scholar]
  72. Kochhar S. Salmon D.A. Planning for COVID-19 vaccines safety surveillance. Vaccine 2020 38 40 6194 6198 10.1016/j.vaccine.2020.07.013 32684499
    [Google Scholar]
  73. Denning D.W. Lee J.Y. Hostetler J.S. Pappas P. Kauffman C.A. Dewsnup D.H. Galgiani J.N. Graybill J.R. Sugar A.M. Catanzaro A. Gallis H. Perfect J.R. Dockery B. Dismukes W.E. Stevens D.A. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 1994 97 2 135 144 10.1016/0002‑9343(94)90023‑X 8059779
    [Google Scholar]
  74. Lionakis M.S. Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet 2003 362 9398 1828 1838 10.1016/S0140‑6736(03)14904‑5 14654323
    [Google Scholar]
  75. Jenks J.D. Hoenigl M. Treatment of aspergillosis. J. Fungi 2018 4 3 98 10.3390/jof4030098 30126229
    [Google Scholar]
  76. Dennis M. Dixon T.J.W. Samuel B. Chapter 76 - Antifungal agents. Medical Microbiology. 4th Ed. University of Texas Medical Branch at Galveston Galveston (TX) 1996
    [Google Scholar]
  77. Meis J.F.G.M. Verweij P.E. Current management of fungal infections. Drugs 2001 61 Suppl1 13 25 10.2165/00003495‑200161001‑00002
    [Google Scholar]
  78. Tobin M.B. Peery R.B. Skatrud P.L. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus. Gene 1997 200 1-2 11 23 10.1016/S0378‑1119(97)00281‑3 9373135
    [Google Scholar]
  79. Lass-Flörl C. Kofler G. Kropshofer G. Hermans J. Kreczy A. Dierich M.P. Niederwieser D. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 1998 42 4 497 502 10.1093/jac/42.4.497 9818749
    [Google Scholar]
  80. Seo K. Akiyoshi H. J-Stage. 1999 Available from: www.jstage.jst.go.jp (Accessed on: 27-Nov-2024).
  81. Mosquera J. Warn P.A. Morrissey J. Moore C.B. Gil-Lamaignere C. Denning D.W. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin b in vitro and outcome in vivo. Anti. Agen. Chem. 2001 45 5 1456 1462 10.1128/AAC.45.5.1456‑1462.2001 11302810
    [Google Scholar]
  82. Kontoyiannis D. Bodey G. Invasive aspergillosis in 2002: an update. Eur. J. Clin. Micr. Inf. Dis. 2002 21 3 161 172 10.1007/s10096‑002‑0699‑z 11957017
    [Google Scholar]
  83. Hsueh P.R. Lau Y.J. Chuang Y.C. Wan J.H. Huang W.K. Shyr J.M. Yan J.J. Yu K.W. Wu J.J. Ko W.C. Yang Y.C. Liu Y.C. Teng L.J. Liu C.Y. Luh K.T. Antifungal susceptibilities of clinical isolates of candida species, cryptococcus neoformans, and aspergillus species from taiwan: Surveillance of multicenter antimicrobial resistance in taiwan program data from 2003. Anti. Age. Chem. 2005 49 2 512 517 10.1128/AAC.49.2.512‑517.2005 15673726
    [Google Scholar]
  84. Bedin Denardi L. Hoch Dalla-Lana B. Pantella Kunz de Jesus F. Bittencourt Severo C. Morais Santurio J. Zanette R.A. Hartz Alves S. In vitro antifungal susceptibility of clinical and environmental isolates of aspergillus fumigatus and Aspergillus flavus in brazil. Bra. J. Inf. Dis. 2018 22 1 30 36 10.1016/j.bjid.2017.10.005 29172033
    [Google Scholar]
  85. Walsh T.J. Anaissie E.J. Denning D.W. Herbrecht R. Kontoyiannis D.P. Marr K.A. Morrison V.A. Segal B.H. Steinbach W.J. Stevens D.A. van Burik J.A. Wingard J.R. Patterson T.F. Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of america. Clin. Infect. Dis. 2008 46 3 327 360 10.1086/525258 18177225
    [Google Scholar]
  86. Uniyal V. Bhatt R.P. Saxena S. Talwar A. Antifungal activity of essential oils and their volatile constituents against respiratory tract pathogens causing aspergilloma and aspergillosis by gaseous contact. J. Appl. Nat. Sci. 2012 4 1 65 70 10.31018/jans.v4i1.224 21336686
    [Google Scholar]
  87. Ngarivhume T. van’t Klooster C.I.E.A. de Jong J.T.V.M. Van der Westhuizen J.H. Medicinal plants used by traditional healers for the treatment of malaria in the chipinge district in zimbabwe. J. Ethno. 2015 159 224 237 10.1016/j.jep.2014.11.011 25449454
    [Google Scholar]
  88. Abdelhalim A. Aburjai T. Hanrahan J. Abdel-Halim H. Medicinal plants used by traditional healers in jordan, the tafila region. Pharm. Mag. 2017 13 49 Suppl. 1 95 10.4103/0973‑1296.203975 28479733
    [Google Scholar]
  89. Pianalto K. Alspaugh J. New horizons in antifungal therapy. J. Fungi 2016 2 4 26 10.3390/jof2040026 29376943
    [Google Scholar]
  90. Scorzoni L. de Paula e Silva A.C.A. Marcos C.M. Assato P.A. de Melo W.C.M.A. de Oliveira H.C. Costa-Orlandi C.B. Mendes-Giannini M.J.S. Fusco-Almeida A.M. Antifungal therapy: New advances in the understanding and treatment of mycosis. Front. Microbiol. 2017 8 36 10.3389/fmicb.2017.00036 28167935
    [Google Scholar]
  91. Pfaller M.A. Diekema D.J. Gibbs D.L. Newell V.A. Ellis D. Tullio V. Rodloff A. Fu W. Ling T.A. Results from the artemis disk global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of candida species to fluconazole and voriconazole as determined by clsi standardized disk diffusion. J. Clin. Microbiol. 2010 48 4 1366 1377 10.1128/JCM.02117‑09 20164282
    [Google Scholar]
  92. Heinz W.J. Einsele H. Caspofungin for treatment of invasive aspergillus infections. Mycoses 2008 51 s1 Suppl. 1 47 57 10.1111/j.1439‑0507.2008.01528.x 18471161
    [Google Scholar]
  93. Denning D.W. Invasive aspergillosis. Clin. Infect. Dis. 1998 26 4 781 803 10.1086/513943 9564455
    [Google Scholar]
  94. Denning D.W. Venkateswarlu K. Oakley K.L. Anderson M.J. Manning N.J. Stevens D.A. Warnock D.W. Kelly S.L. Itraconazole resistance in aspergillus fumigatus. Anti. Age. Chem. 1997 41 6 1364 1368 10.1128/AAC.41.6.1364 9174200
    [Google Scholar]
  95. Denning D. Radford S.A. Oakley K.L. Hall L. Johnson E.M. Warnock D.W. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of aspergillus fumigatus infection. J. Anti. Chem. 1997 40 3 401 414 10.1093/jac/40.3.401 9338494
    [Google Scholar]
  96. Verweij P.E. Mensink M. Rijs A.J. Donnelly J.P. Meis J.F. Denning D.W. In-vitro activities of amphotericin b, itraconazole and voriconazole against 150 clinical and environmental aspergillus fumigatus isolates. J. Anti. Chem. 1998 42 3 389 392 10.1093/jac/42.3.389 9786480
    [Google Scholar]
  97. Verweij P.E. Oakley K.L. Morrissey J. Morrissey G. Denning D.W. Efficacy of LY303366 against amphotericin b-susceptible and resistant aspergillus fumigatus in a murine model of invasive aspergillosis. Anti. Age. Chem. 1998 42 4 873 878 10.1128/AAC.42.4.873 9559799
    [Google Scholar]
  98. Odds F.C. Van Gerven F. Espinel-Ingroff A. Bartlett M.S. Ghannoum M.A. Lancaster M.V. Pfaller M.A. Rex J.H. Rinaldi M.G. Walsh T.J. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Anti. Agen. Chem. 1998 42 2 282 288 10.1128/AAC.42.2.282 9527773
    [Google Scholar]
  99. Al Aboody M.S. Mickymaray S. Anti-fungal efficacy and mechanisms of flavonoids. Antibiotics 2020 9 2 45 10.3390/antibiotics9020045 31991883
    [Google Scholar]
  100. Rao A. Zhang Y. Muend S. Rao R. Mechanism of antifungal activity of terpenoid phenols resembles calcium stress and inhibition of the tor pathway. Anti. Agen. Chem. 2010 54 12 5062 5069 10.1128/AAC.01050‑10 20921304
    [Google Scholar]
  101. Nywening A.V. Rybak J.M. Rogers P.D. Fortwendel J.R. Mechanisms of triazole resistance in aspergillus fumigatus. Environ. Microbiol. 2020 22 12 4934 4952 10.1111/1462‑2920.15274 33047482
    [Google Scholar]
  102. Lucio J. Gonzalez-Jimenez I. Rivero-Menendez O. Alastruey-Izquierdo A. Pelaez T. Alcazar-Fuoli L. Mellado E. Point mutations in the 14-α sterol demethylase cyp51a or cyp51c could contribute to azole resistance in Aspergillus flavus. Genes 2020 11 10 1217 10.3390/genes11101217 33080784
    [Google Scholar]
  103. Blum G. Perkhofer S. Haas H. Schrettl M. Würzner R. Dierich M.P. Lass-Flörl C. Potential basis for amphotericin b resistance in aspergillus terreus. Anti. Agen. Chem. 2008 52 4 1553 1555 10.1128/AAC.01280‑07 18268082
    [Google Scholar]
  104. Annunziato G. Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: A review. Int. J. Mol. Sci. 2019 20 23 5844 10.3390/ijms20235844 31766441
    [Google Scholar]
  105. Bhowmick B. Phytopathology V.V.I. AGRIS. International system for agricultural science and technology. 1981 Available from: http://www.fao.org/agris
  106. Kurucheve V. Ezhilan J.G. Jayaraj J. Screening of higher plants for fungitoxicity against rhizoctonia solani in vitro. Indian Phytopathol. 1997 50 235 241
    [Google Scholar]
  107. Cichewicz R.H. Thorpe P.A. The antimicrobial properties of chile peppers (Capsicum species) and their uses in Mayan medicine. J. Ethnoph. 1996 52 2 61 70 10.1016/0378‑8741(96)01384‑0 8735449
    [Google Scholar]
  108. Arora DS Some indian spices and their antimicrobial properties. Ethno. Fun. Bio. Pub. onl. Springer Boston, MA 1999 33 40 10.1007/978‑1‑4615‑4815‑7_4
    [Google Scholar]
  109. Cowan M.M. Plant products as antimicrobial agents. Clin. Microbiol. Rev. 1999 12 4 564 582 10.1128/CMR.12.4.564 10515903
    [Google Scholar]
  110. Ciocan I.D. Bra I. Plant products and antimicrobial agents. 12 4 564 582 10.1128/cmr.12.4.564 10515903
    [Google Scholar]
  111. González-Lamothe R. Mitchell G. Gattuso M. Diarra M.S. Malouin F. Bouarab K. Plant antimicrobial agents and their effects on plant and human pathogens. Int. J. Mol. Sci. 2009 10 8 3400 3419 10.3390/ijms10083400 20111686
    [Google Scholar]
  112. Höfling J.F. Anibal P.C. Obando-Pereda G.A. Peixoto I.A.T. Furletti V.F. Foglio M.A. Gonçalves R.B. Antimicrobial potential of some plant extracts against candida species. Braz. J. Biol. 2010 70 4 1065 1068 10.1590/S1519‑69842010000500022 21180915
    [Google Scholar]
  113. Pandey A.K. Kumar S. Perspective on plant products as antimicrobials agents: A review. Pharmacologia 2013 4 7 469 480 10.5567/pharmacologia.2013.469.480
    [Google Scholar]
  114. Karunamoorthi K. Jegajeevanram K. Vijayalakshmi J. Mengistie E. Traditional medicinal plants. J. Evid. Bas. Complem. Altern. Med. 2013 18 1 67 74 10.1177/2156587212460241
    [Google Scholar]
  115. Ali-Shtayeh M.S. Abu Ghdeib S.I. Antifungal activity of plant extracts against dermatophytes. Mycoses 1999 42 11-12 665 672 10.1046/j.1439‑0507.1999.00499.x 10680445
    [Google Scholar]
  116. Farnsworth N.R. Akerele O. Bingel A.S. Soejarto D.D. Guo Z. Medicinal plants in therapy. Bull. Wor. Hea. Org. 1985 63 6 965 981 3879679
    [Google Scholar]
  117. Masih H. Peter J.K. Tripathi P. A comparative evaluation of antifungal activity of medicinal plant extracts and chemical fungicides against four plant pathogens. Int. J. Curr. Microbiol. Appl. Sci. 2014 3 97 109
    [Google Scholar]
  118. Massiha A. Muradov P.Z. Comparison of antifungal activity of extracts of ten plant species and griseofulvin against human pathogenic dermatophytes. Zahedan J. Res. Med. Sci. 2015 17 10 17 10.17795/zjrms‑2096
    [Google Scholar]
  119. Borris R.P. Natural products research: perspectives from a major pharmaceutical company. J. Ethnopharmacol. 1996 51 1-3 29 38 10.1016/0378‑8741(95)01347‑4 9213624
    [Google Scholar]
  120. Arif T. Bhosale J.D. Kumar N. Mandal T.K. Bendre R.S. Lavekar G.S. Dabur R. Natural products – antifungal agents derived from plants. J. Asian Nat. Prod. Res. 2009 11 7 621 638 10.1080/10286020902942350 20183299
    [Google Scholar]
  121. Lewis W.H. Elvin-Lewis M.P. Medicinal plants as sources of new therapeutics. Ann. Mo. Bot. Gard. 1995 82 1 16 10.2307/2399976
    [Google Scholar]
  122. George M. Pandalai K.M. Investigations on plant antibiotics. part iv. further search for antibiotic substances in indian medicinal plants. Indian J. Med. Res. 1949 37 169 181
    [Google Scholar]
  123. Rojas A. Hernandez L. Pereda-Miranda R. Mata R. Screening for antimicrobial activity of crude drug extracts and pure natural products from Mexican medicinal plants. J. Ethnopharmacol. 1992 35 3 275 283 10.1016/0378‑8741(92)90025‑M 1548900
    [Google Scholar]
  124. Young D.H. Michelotti E.L. Swindell C.S. Krauss N.E. Antifungal properties of taxol and various analogues. Experientia 1992 48 9 882 885 10.1007/BF02118425 1356825
    [Google Scholar]
  125. Ruszkowska J. Wróbel J.T. Tryptophan-derived sulfur-containing phytoalexins - A general overview. Advances in Experimental Medicine and Biology. Kluwer Academic/Plenum Publishers 2003 Vol. 527 629 636
    [Google Scholar]
  126. Geissman T.A. Flavonoid compounds, tannins, lignins and, related compounds. Elsevier B.V. 1963 9 1963 213 250 10.1016/B978‑1‑4831‑9718‑0.50018‑7
    [Google Scholar]
  127. Schultes R.E. The Kingdom of Plants. Mc Graw-Hill Book Co 1978 179
    [Google Scholar]
  128. Abad M.J. Ansuategi M. Bermejo P. Active antifungal substances from natural sources. Arkivoc 2006 2007 7 116 145 10.3998/ark.5550190.0008.711
    [Google Scholar]
  129. Ríos J.L. Recio M.C. Medicinal plants and antimicrobial activity. J. Ethnopharmacol. 2005 100 1-2 80 84 10.1016/j.jep.2005.04.025 15964727
    [Google Scholar]
  130. Dorman H. Microbiology SDJ of applied, 2000 undefined. Antimicrobial agents from plants: Antibacterial activity of plant volatile oils. 2000 Available from: academic.oup.com
  131. Kalemba D. Kunicka A. Antibacterial and antifungal properties of essential oils. Curr. Med. Chem. 2003 10 10 813 829 10.2174/0929867033457719 12678685
    [Google Scholar]
  132. Guynot M.E. Ramos A.J. Setó L. Purroy P. Sanchis V. Marín S. Antifungal activity of volatile compounds generated by essential oils against fungi commonly causing deterioration of bakery products. J. Appl. Microbiol. 2003 94 5 893 899 10.1046/j.1365‑2672.2003.01927.x 12694455
    [Google Scholar]
  133. Pawar V.C. Thaker V.S. In vitro efficacy of 75 essential oils against Aspergillus niger. Mycoses 2006 49 4 316 323 10.1111/j.1439‑0507.2006.01241.x 16784447
    [Google Scholar]
  134. Cavaleiro C. Pinto E. Gonçalves M.J. Salgueiro L. Antifungal activity of juniperus essential oils against dermatophyte, Aspergillus and Candida strains. J. Appl. Micro. 2006 100 6 1333 1338 10.1111/j.1365‑2672.2006.02862.x 16696681
    [Google Scholar]
  135. Pinto E. Pina-Vaz C. Salgueiro L. Gonçalves M.J. Costa-de-Oliveira S. Cavaleiro C. Palmeira A. Rodrigues A. Martinez-de-Oliveira J. Antifungal activity of the essential oil of thymus pulegioides on candida, Aspergillus and dermatophyte species. J. Med. Micro. 2006 55 10 1367 1373 10.1099/jmm.0.46443‑0 17005785
    [Google Scholar]
  136. Tullio V. Nostro A. Mandras N. Dugo P. Banche G. Cannatelli M.A. Cuffini A.M. Alonzo V. Carlone N.A. Antifungal activity of essential oils against filamentous fungi determined by broth microdilution and vapour contact methods. J. Appl. Microbiol. 2007 102 6 1544 1550 10.1111/j.1365‑2672.2006.03191.x 17578419
    [Google Scholar]
  137. Bansod S. Rai M. Antifungal activity of essential oils from indian medicinal plants against human pathogenic aspergillus fumigatus and A. niger. Wor. J. Med. Sci. 2008 3 81 88
    [Google Scholar]
  138. Alizadeh A. Zamani E. Sharaifi R. Javan-Nikkhah M. Nazari S. Antifungal activity of some essential oils against toxigenic aspergillus species. Commun. Agric. Appl. Biol. Sci. 2010 75 4 761 767 21534488
    [Google Scholar]
  139. Jain S.K. Agrawal S.C. Fungistatic activity of some perfumes against otomycotic pathogens. Mycoses 2002 45 3-4 88 90 10.1046/j.1439‑0507.2002.00730.x 12000507
    [Google Scholar]
  140. Soliman K.M. Badeaa R.I. Effect of oil extracted from some medicinal plants on different mycotoxigenic fungi. Food Chem. Toxicol. 2002 40 11 1669 1675 10.1016/S0278‑6915(02)00120‑5 12176092
    [Google Scholar]
  141. Thanaboripat D. Suvathi Y. Srilohasin P. Inhibitory effect of essential oils on the growth of aspergillus flavus. Curr. Appl. Sci. Technol. 2007 7 1 7
    [Google Scholar]
  142. Mahesh B Satish S Drug H. Antimicrobial activity of some important medicinal plant against plant and human pathogens. Wor. Jour. Agric. Sci. 2008 4 839 843
    [Google Scholar]
  143. Villanueva J.M. Arugay M.A.V. Ramos R.Z.H. In vitro antimycotic activity of four medicinal plants versus clotrimazole in the treatment of otomycosis: a preliminary study. Phil. J. Otolaryngology-Head Nec. Sur. 2008 23 1 5 8 10.32412/pjohns.v23i1.759
    [Google Scholar]
  144. Shaik G.V. Antifungal activity of an indian medicinal plant argyreia involucrata. Int. J. Res. Pharm. Biomed. Sci. 2011 2 1841 1844
    [Google Scholar]
  145. Bhalodia N.R. Nariya P.B. Shukla V.J. Antibacterial and antifungal activity from flower extracts of cassia fistula l.: An ethnomedicinal plant. Int. J. Pharm. Tech. Res. 2011 3 160 168
    [Google Scholar]
  146. Gahlaut A. Dabur R. Chhillar A.K. Anti-aspergillus activity of selected medicinal plants. J. Pharm. Res. 2013 6 4 419 422 10.1016/j.jopr.2013.02.029
    [Google Scholar]
  147. Frisby T. Antifungal activity in extracts of plants from southwestern oklahoma against aspergillus flavus. Okla. Nati. Pla. Rec. 2015 15 1 78 95 10.22488/okstate.17.100115
    [Google Scholar]
  148. Omidpanah S. Haseli A. Manayi A. Evaluation of antifungal properties of some medicinal plants against aspergillus flavus isolated from contaminated corn in vitro. Mediterr. J. Chem. 2015 3 6 1093 1099 10.13171/mjc.3.6.2015.01.09.13.22.manayi
    [Google Scholar]
  149. Njoki LM Okoth SA Wachira PM Effects of medicinal plant extracts and photosensitization on aflatoxin producing Aspergillus flavus. Int. J. Micro. 2017 2017 9 10.1155/2017/5273893 28539938
    [Google Scholar]
  150. Chekuri S Jyoti B A Evaluation of anti microbial and anti fungal activity of acalyphaindica l., leaf extract. Int. J. Phar. Phyt. Res. 2018 10 11931 10.25258/phyto.v10i01.11931
    [Google Scholar]
  151. Tajehmiri A. Rahmani M.R. Moosavi S.S. Davari K. Ebrahimi S.S. Antifungal effects of six herbal extracts against Aspergillus sp. and compared to amphotericin B and nystatin. Inter. J. adva. app. sci. 2018 5 7 53 57 10.21833/ijaas.2018.07.007
    [Google Scholar]
  152. Mbunde M.V.N. Mabiki F. Innocent E. Andersson P.G. Antifungal activity of single and combined extracts of medicinal plants from southern highlands of tanzania. J. Phar. Phyt. 2019 8 181 187
    [Google Scholar]
  153. Aqil F. Ahmad I. Broad-spectrum antibacterial and antifungal properties of certain traditionally used indian medicinal plants. Wor. J. Mic. Bio. 2003 19 6 653 657 10.1023/A:1025128104056
    [Google Scholar]
  154. Elansary H.O. Salem M.Z.M. Ashmawy N.A. Yessoufou K. El-Settawy A.A.A. In vitro antibacterial, antifungal and antioxidant activities of Eucalyptus spp. leaf extracts related to phenolic composition. Nat. Prod. Res. 2017 31 24 2927 2930 10.1080/14786419.2017.1303698 28299978
    [Google Scholar]
  155. Tian F. Woo S.Y. Lee S.Y. Chun H.S. p-Cymene and its derivatives exhibit antiaflatoxigenic activities against aspergillus flavus through multiple modes of action. Appl. Biolog. Chem. 2018 61 5 489 497 10.1007/s13765‑018‑0382‑4
    [Google Scholar]
  156. Tan L.F. Yap V.L. Rajagopal M. Wiart C. Selvaraja M. Leong M.Y. Tan P.L. Plant as an alternative source of antifungals against Aspergillus infections: A review. Plants 2022 11 22 3009 10.3390/plants11223009 36432738
    [Google Scholar]
  157. Aala F Yusuf UK Nulit R Rezaie S Inhibitory effect of allicin and garlic extracts on growth of cultured hyphae. Ira. J. Bas. Med. Sci. 2014 17 3 150 154 24847416
    [Google Scholar]
  158. Rocha O.B. do Carmo Silva L. de Carvalho Júnior M.A.B. de Oliveira A.A. de Almeida Soares C.M. Pereira M. In vitro and in silico analysis reveals antifungal activity and potential targets of curcumin on paracoccidioides spp. Braz. J. Microbiol. 2021 52 4 1897 1911 10.1007/s42770‑021‑00548‑6 34324170
    [Google Scholar]
  159. Wang J. Zhang X. Gao L. Wang L. Song F. Zhang L. Wan Y. The synergistic antifungal activity of resveratrol with azoles against Candida albicans. Lett. Appl. Microbiol. 2021 72 6 688 697 10.1111/lam.13458 33550599
    [Google Scholar]
  160. Almshawit H. Macreadie I. Fungicidal effect of thymoquinone involves generation of oxidative stress in Candida glabrata. Microbiol. Res. 2017 195 81 88 10.1016/j.micres.2016.11.008 28024529
    [Google Scholar]
  161. da Silva A.R. de Andrade Neto J.B. da Silva C.R. Campos R.S. Costa Silva R.A. Freitas D.D. do Nascimento F.B.S.A. de Andrade L.N.D. Sampaio L.S. Grangeiro T.B. Magalhães H.I.F. Cavalcanti B.C. de Moraes M.O. Nobre Júnior H.V. Berberine antifungal activity in fluconazole-resistant pathogenic yeasts: Action mechanism evaluated by flow cytometry and biofilm growth inhibition in Candida spp. Anti. Agen. Chem. 2016 60 6 3551 3557 10.1128/AAC.01846‑15 27021328
    [Google Scholar]
  162. Vuong M.F. Hollingshead C.M Waymack J.R. Aspergillosis. StatPearls StatPearls Publishing Treasure Island (FL) 2022 29489184
    [Google Scholar]
  163. Shahhosseini N. Khabiri A. Bagheri F. The spectrum of diseases caused by Aspergillus fumigatus. Iran. J. Clin. Infect. Dis. 2011 6 136 141
    [Google Scholar]
  164. Kiswii T.M. Efficacy of selected medicinal plants from eastern kenya against Aspergillus flavus. J. Plant Sci. 2014 2 226
    [Google Scholar]
  165. Malaba Makoye P. Mrutu S. Daniel J. Nyangabo Mbunde M. Sempombe J. Mugoyela V. In vitro antibacterial and antifungal activities of sorindeia madagascariensis and albizia harveyi stem barks. Pharm. Sci. Res. 2022 9 51 58
    [Google Scholar]
  166. Ullah R. Touseef I. Abid R. Farid A. Ahmad S. Ali El Enshasy H. Aksoy A. Aljarba N.H. Mohamed Al-Hazani T. Muzammal M. Ghazanfar S. Exploitation of selected plant extracts as bio-control against fungal contaminants in animal feed. J. King Saud Univ. Sci. 2023 35 5 102685 10.1016/j.jksus.2023.102685
    [Google Scholar]
  167. Aljeldah M.M. Antioxidant and antimicrobial potencies of chemically-profiled essential oil from Asteriscus graveolens against clinically-important pathogenic microbial strains. Molecules 2022 27 11 3539 10.3390/molecules27113539 35684475
    [Google Scholar]
  168. Villanueva J.M. Arugay M.A.V. Ramos R.Z.H. In vitro antimycotic activity of four medicinal plants versus clotrimazole in the treatment of otomycosis: a preliminary study. Phili. J. Otolaryngol.-Hea. Ne. Surg. 2008 23 1 5 8 10.32412/pjohns.v23i1.759
    [Google Scholar]
  169. Mbunde M.V.N. Mabiki F. Innocent E. Andersson P.G. Antifungal activity of single and combined extracts of medicinal plants from Southern Highlands of Tanzania. J. Pharmacogn. Phytochem. 2019 8 181 187
    [Google Scholar]
  170. Dikhoba P.M. Mongalo N.I. Elgorashi E.E. Makhafola T.J. Antifungal and anti-mycotoxigenic activity of selected South African medicinal plants species. Heliyon 2019 5 10 e02668 10.1016/j.heliyon.2019.e02668 31692684
    [Google Scholar]
  171. Orole O. Adejumo T. Orole R. Antifungal activity of nine medicinal plants against aspergillus species from cocoa beans (Theobroma cacao). J. Agri. Ecol. Res. Inter. 2016 7 2 1 11 10.9734/JAERI/2016/24602
    [Google Scholar]
  172. Sharanya M. Oviya I.R. Poornima V. Jeyam M. Antifungal susceptibility testing of few medicinal plant extracts against aspergillus spp. and microsporum sp. J. Appl. Pharm. Sci. 2013 3 10.7324/JAPS.2013.38.S3
    [Google Scholar]
  173. Senguttuvan J. Paulsamy S. Krishnamoorthy K. In vitro antifungal activity of leaf and root extracts of the medicinal plant, Hypochaeris radicata L. Int. J. Pharm. Pharm. Sci. 2013 5 758 761
    [Google Scholar]
  174. Njoki LM Okoth SA Wachira PM Effects of medicinal plant extracts and photosensitization on aflatoxin producing aspergillus flavus (raper and fennell). Int. J. Mic. 2017 2017 5273893 10.1155/2017/5273893 28539938
    [Google Scholar]
  175. Kannahi M. Vinotha K. Antimicrobial activity of Lawsonia inermis leaf extracts against some human pathogens. 2013 Available from: https://www.cabdirect.org/globalhealth/abstract/20133422867 (Accessed on: 28-12-2013).
  176. Das S. Singh V.K. Dwivedy A.K. Chaudhari A.K. Dubey N.K. Myristica fragrans essential oil nanoemulsion as novel green preservative against fungal and aflatoxin contamination of food commodities with emphasis on biochemical mode of action and molecular docking of major components. Lebensm. Wiss. Technol. 2020 130 109495 10.1016/j.lwt.2020.109495
    [Google Scholar]
  177. Mohamed EAA Muddathir AM Osman MA Antimicrobial activity, phytochemical screening of crude extracts, and essential oils constituents of two Pulicaria spp. gro. Sudan. Sci. Rep. 2020 10 1 17148 10.1038/s41598‑020‑74262‑y 33051571
    [Google Scholar]
  178. Ebani VV Nardoni S Bertelloni F Activity of salvia dolomitica and salvia somalensis essential oils against bacteria, molds and yeasts. Mol 2018 23 2 396 10.3390/molecules23020396 29438274
    [Google Scholar]
  179. Kim H.M. Kwon H. Kim K. Lee S.E. Antifungal and antiaflatoxigenic activities of 1,8-cineole and t-cinnamaldehyde on Aspergillus flavus. Appl. Sci. 2018 8 9 1655 10.3390/app8091655
    [Google Scholar]
  180. Ahmad A. Khan A. Akhtar F. Yousuf S. Xess I. Khan L.A. Manzoor N. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against candida. Eur. J. Clin. Microbiol. Infect. Dis. 2011 30 1 41 50 10.1007/s10096‑010‑1050‑8 20835742
    [Google Scholar]
  181. Neri F. Mari M. Brigati S. Control of Penicillium expansum by plant volatile compounds. Plant Pathol. 2006 55 1 100 105 10.1111/j.1365‑3059.2005.01312.x
    [Google Scholar]
  182. Ultee A. Bennik M.H.J. Moezelaar R. The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen bacillus cereus. Appl. Environ. Microbiol. 2002 68 4 1561 1568 10.1128/AEM.68.4.1561‑1568.2002 11916669
    [Google Scholar]
  183. Sharaf E.F. Al-Zaidi H.S. In vitro antifungal activity of some indigenous medicinal plant extracts against five isolates of Aspergillus fumigatus. Indian J. Pharm. Sci. 2021 83 695 700
    [Google Scholar]
  184. Khan M.S.A. Ahmad I. In vitro antifungal, anti-elastase and anti-keratinase activity of essential oils of cinnamomum-, syzygium- and cymbopogon-species against aspergillus fumigatus and trichophyton rubrum. Phytomedicine 2011 19 1 48 55 10.1016/j.phymed.2011.07.005 21893402
    [Google Scholar]
  185. Tian J. Huang B. Luo X. Zeng H. Ban X. He J. Wang Y. The control of Aspergillus flavus with cinnamomum jensenianum hand.-mazz essential oil and its potential use as a food preservative. Food Chem. 2012 130 3 520 527 10.1016/j.foodchem.2011.07.061
    [Google Scholar]
  186. Da X Nishiyama Y Tie D Hein KZ Yamamoto O Morita E Antifungal activity and mechanism of action of ou-gon (scutellaria root extract) components against pathogenic fungi. Sci. Repor. 2019 9 1 1683 10.1038/s41598‑019‑38916‑w. 30737463
    [Google Scholar]
  187. Abyaneh M.R. Allameh A. Al-Tiraihi T. Shams M. Studies on the mode of action of neem (Azadirachta indica) leaf and seed extracts on morphology and aflatoxin production ability of aspergillus parasiticus. Acta Hortic. 2005 675 123 127 10.17660/ActaHortic.2005.675.17
    [Google Scholar]
  188. Somai B.M. Belewa V. Frost C. Tulbaghia violacea (Harv) exerts its antifungal activity by reducing ergosterol production in Aspergillus flavus. Curr. Microbiol. 2021 78 8 2989 2997 10.1007/s00284‑021‑02546‑1 34100987
    [Google Scholar]
  189. Cruz A. Sánchez-Hernández E. Teixeira A. Oliveira R. Cunha A. Martín-Ramos P. Phytoconstituents and ergosterol biosynthesis-targeting antimicrobial activity of nutmeg (Myristica fragans Houtt.) against phytopathogens. Molecules 2024 29 2 471 10.3390/molecules29020471 38257384
    [Google Scholar]
  190. Pannu A. Kapila S. Secrain S. Phytochemical characterization and antifungal activity of Marchantia polymorpha L. against Rhizoctonia solani. Pharmacol Res. 2024 11 100426
    [Google Scholar]
  191. Mustafa KH Khorshidi J Vafaee Y Rastegar A Morshedloo MR Hossaini S Correction: phytochemical profile and antifungal activity of essential oils obtained from different mentha longifolia L. Acce. grow. wi. Ira. Ir. 2024 24:539. 10.1186/s12870‑024‑05237‑8 38872091
    [Google Scholar]
  192. Siroua K. El Ghallab Y. Aït Mouss R. Kadiri F. Belamine H. El Kouali M. Kenz A. Chemical composition of essential oil from invasive moroccan cyperus rotundus l., in vitro antimicrobial and antiradical activities, and in silico molecular docking of major compounds on drug efflux pumps. S. Afr. J. Bot. 2022 147 782 789 10.1016/j.sajb.2022.03.020
    [Google Scholar]
  193. Al-Otibi F. Alshahrani R.A. Alharbi R.I. Yassin M.T. Phytochemical analysis and antifungal efficiency of Origanum majorana extracts against some phytopathogenic fungi causing tomato damping-off diseases. Open Chem. 2023 21 1 20230181 10.1515/chem‑2023‑0181
    [Google Scholar]
  194. Trindade L.A. Cordeiro L.V. de Figuerêdo Silva D. Figueiredo P.T.R. de Pontes M.L.C. de Oliveira Lima E. de Albuquerque Tavares Carvalho A. The antifungal and antibiofilm activity of cymbopogon nardus essential oil and citronellal on clinical strains of candida albicans. Braz. J. Microbiol. 2022 53 3 1231 1240 10.1007/s42770‑022‑00740‑2 35386096
    [Google Scholar]
/content/journals/covid/10.2174/0126667975333157241227074402
Loading
Plant-based Therapeutics for Aspergillus Co-infections in COVID-19 Patients Illuminating Phytochemical Mechanisms
Bentham Science Publishers ; https://doi.org/10.2174/0126667975333157241227074402
/content/journals/covid/10.2174/0126667975333157241227074402
/content/journals/covid/10.2174/0126667975333157241227074402
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: plant-based therapeutics ; aspergillosis ; herbal therapy ; natural antifungal-agents ; COVID-19 ; aspergillus co-infections
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test